NASDAQ: ALZN
Linkedin Facebook-f Twitter Youtube Instagram
Alzamend Neuro, Inc.
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers
Menu
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Presentations
  • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts
Sep 22, 2022 8:00am EDT

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Jul 18, 2022 8:00am EDT

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Jun 03, 2022 8:00am EDT

Alzamend Neuro to Present at the 12th Annual LD Micro Invitational

May 17, 2022 8:00am EDT

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

May 05, 2022 8:00am EDT

Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Apr 28, 2022 6:30am EDT

Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Apr 11, 2022 8:00am EDT

Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s

Apr 04, 2022 8:00am EDT

Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

Mar 28, 2022 8:00am EDT

Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Dec 17, 2021 9:00am EST

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Making Alzheimer’s
Just a Memory™

About

  • Overview
  • Management
  • Board of Directors
  • Governance

Investor Relations

  • Overview
  • News & Events
  • Company Info
  • Presentations
  • Financial Results
  • Stock Data
  • SEC Filings
  • Governance

Other

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Safe Harbor

© 2016-22 Alzamend Neuro, Inc. All rights reserved.

Linkedin Facebook-f Twitter Youtube Instagram
Skip to content